H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.
Published first on TheFly
H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.
Published first on TheFly